文献速递乳腺癌

阿贝西利联合内分泌治疗早期乳腺癌的总生存获益

Overall survival with abemaciclib in early breast cancer.
PubMed 文献 · Ann Oncol · 2025-10-17

monarchE Ⅲ期试验纳入 5637 例 HR 阳性、HER2 阴性、淋巴结阳性高危早期乳腺癌患者,随机接受内分泌治疗±阿贝西利 2 年。中位随访 76.2 个月,阿贝西利-ET 组死亡风险降低 15.8%(HR 0.842,95%CI 0.722-0.981,P=0.027),7 年 OS 86.8% vs 85.0%。IDFS 和 DRFS 获益持续。

要点

  • 阿贝西利联合内分泌治疗显著改善高危早期乳腺癌总生存。
  • 7 年 OS 绝对差异 1.8%,7 年 IDFS 绝对差异 6.5%。
  • 长期安全性数据未提示延迟毒性担忧。

核心结论

  • 在 HR 阳性、HER2 阴性、淋巴结阳性高危早期乳腺癌中,辅助阿贝西利联合内分泌治疗较单用内分泌治疗显著改善总生存。
  • 7 年时阿贝西利-ET 持续显示 IDFS 和 DRFS 获益。

研究设计与样本

  • monarchE 为Ⅲ期随机试验(NCT03155997),共随机 5637 例患者,阿贝西利-ET 组 2808 例,ET 组 2829 例。
  • 患者接受内分泌治疗至少 5 年,随机加或不加阿贝西利 2 年。
  • 本文报告主要 OS 结果(关键次要终点)及更新的 IDFS 和 DRFS 估计。

主要发现

  • 中位随访 76.2 个月,意向治疗人群共 661 例死亡,阿贝西利-ET 组死亡风险较 ET 组降低 15.8%(HR 0.842,95%CI 0.722-0.981,P=0.027),达到预设显著性边界。
  • 7 年 OS 阿贝西利-ET 组为 86.8%,ET 组为 85.0%,绝对差异 1.8%。
  • OS 获益在预设亚组中一致。
  • 阿贝西利-ET 组带转移性疾病生存者比例为 6.4%,ET 组为 9.4%。
  • IDFS 持续改善(HR 0.734,95%CI 0.657-0.820),7 年 IDFS 77.4% vs 70.9%,绝对差异 6.5%。

关键数值与推荐

  • OS 风险比 0.842(95%CI 0.722-0.981),P=0.027。
  • 7 年 OS 率:阿贝西利-ET 86.8%,ET 85.0%。
  • 7 年 IDFS 率:阿贝西利-ET 77.4%,ET 70.9%。
  • 7 年 DRFS 率:阿贝西利-ET 80.0%,ET 74.9%。

临床怎么用

  • 对于 HR 阳性、HER2 阴性、淋巴结阳性高危早期乳腺癌,辅助阿贝西利联合内分泌治疗可作为改善长期生存的治疗选择。
  • 长期安全性数据未提示延迟毒性担忧,支持该方案在辅助治疗中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant abemaciclib combined with endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). The impact on overall survival (OS) remained unknown. PATIENTS AND METHODS: In the phase III monarchE trial (NCT03155997), patients received ET for at least 5 years with or without abemaciclib for 2 years. In this article, we report the primary OS results, a key secondary endpoint, and updated estimates of IDFS and distant relapse-free survival (DRFS). RESULTS: Overall, 5637 patients underwent randomization, with 2808 assigned to abemaciclib-ET, and 2829 to ET. In the intent-to-treat population, with a median follow-up of 76.2 months, abemaciclib-ET resulted in a 15.8% lower risk of death than ET [661 deaths; hazard ratio 0.842, 95% confidence interval (CI) 0.722-0.981, P = 0.027], meeting the prespecified boundary for significance. The 7-year OS was 86.8% with abemaciclib-ET and 85.0% with ET (absolute difference, 1.8%). OS benefit was consistent across prespecified subgroups. In addition to patients who had already died of metastatic disease, fewer patients in the abemaciclib-ET arm were living with metastatic disease compared with the ET arm (6.4% versus 9.4%). Sustained improvement was demonstrated in IDFS and DRFS (hazard ratio 0.734, 95% CI 0.657-0.820 and hazard ratio 0.746, 95% CI 0.662-0.840, respectively). Seven-year IDFS was 77.4% with abemaciclib-ET and 70.9% with ET (absolute difference, 6.5%) and 7-year DRFS were 80.0% and 74.9% (absolute difference, 5.1%). The long-term safety data compiled did not support any concerns of delayed toxicities. CONCLUSIONS: Adjuvant abemaciclib-ET resulted in a statistically significant and clinically meaningful improvement in OS compared with ET in patients with HR-positive, HER2-negative, node-positive, high-risk EBC. At 7 years, abemaciclib-ET continued to demonstrate a sustained IDFS and DRFS benefit.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Johnston S, Martin M, O'Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2025. PMID: 41110697. doi:10.1016/j.annonc.2025.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。